STAT+: Merck is urged by patient groups to ensure widespr...

What’s Happening

Okay so Advocacy groups from 30 countries are urging Merck to create a global access strategy for its once-a-month HIV prevention pill that is still in clinical trials.

Pharmalot Pharmalot STAT Plus: Pharmalittle: Were reading about FDA rejecting a Moderna vaccine, compounding in the crosshairs and more By Ed Silverman Pharmalot Pharmalot STAT Plus: Trump administration revives effort to launch pilot initiative reworking drug discount program By Ed Silverman Pharmalot Pharmalot STAT Plus: Pharmalittle: Were reading about FDA rejecting a rare disease drug, a warning to a Hims compounding pharmacy and more By Ed Silverman Pharmalot Pharmalot STAT Plus: OHSU board votes to negotiate with NIH and possibly transform its primate center into an animal sanctuary By Ed Silverman Pharmalot Pharmalot STAT Plus: FDA warned a Hims & Hers compounder after finding bugs and failing to report a serious side effect By Ed Silverman STAT Plus: Vertex’s CRISPR treatment for sickle cell disease hits unexpected roadblock By Jason Mast STAT Plus: A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment By Adam Feuerstein STAT Plus: Prasad overruled FDA staff to reject Modernas flu vaccine app By Lizzy Lawrence STAT Plus: FDA refuses to review Moderna’s influenza vaccine By Matthew Herper and Helen Branswell STAT Plus: Nektar Therapeutics is trying to stage a comeback. (yes, really)

Why This Matters

This is the kind of health news that affects everyday decisions.

Health experts are weighing in on what this means for people.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

Thoughts? Drop them below.